Sarah J. Lawless

Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres.

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres.

Journal: British journal of haematology

Published: February 20, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica

Published: January 21, 2026

Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland.

Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland.

Journal: EJHaem

Published: November 27, 2024

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Journal: British journal of haematology

Published: June 11, 2024

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Journal: Bone marrow transplantation

Published: June 07, 2024

TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.

TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.

Journal: Frontiers in oncology

Published: March 31, 2022

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.

Journal: Haematologica

Published: December 21, 2021

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 22, 2021

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Journal: Blood

Published: May 14, 2020

Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.

Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.

Journal: Endocrine-related cancer

Published: April 04, 2020

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Journal: Haematologica

Published: March 29, 2019

(32)P in the treatment of myeloproliferative disorders.

(32)P in the treatment of myeloproliferative disorders.

Journal: The Ulster medical journal

Published: September 08, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026